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Abstract: Introduction: Parenteral form of lidocaine is the best-known source of lidocaine poisoning. This study aimed
to evaluate the characteristics of acute lidocaine toxicity . Methods: In this retrospective cross-sectional study,
demographics, clinical presentation, laboratory findings, and outcome of patients intoxicated with lidocaine
(based on ICD10 codes) admitted to Loghman Hakim Hospital, during April 2007 to March 2014 were analyzed.
Results: 30 cases with the mean age of 21.83 ± 6.57 year were studied (60% male). All subjects had used either
6.5% lidocaine spray or 2% topical formulations of lidocaine. The mean consumed dose of lidocaine was 465 ±
318.17 milligrams. The most frequent clinical presentations were nausea and vomiting (50%), seizure (33.3%),
and loss of consciousness (16.7%). 22 (73.3%) cases had normal sinus rhythm, 4 (13.3%) bradycardia, 2 (6.7%)
ventricular tachycardia, and 2 (6.7%) had left axis deviation. 11 (36.6%) cases were intubated and admitted to
intensive care unit (ICU) for 6.91 ± 7.16 days. Three patients experienced status epilepticus that led to cardiac
arrest, and death (all cases with suicidal intention). Conclusion: Based on the results of this study, most cases
of topical lidocaine toxicity were among < 40-year-old patients with a male to female ratio of 1.2, with suicidal
attempt in 90%, need for intensive care in 36.6%, and mortality rate of 10%.
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1. Introduction
L
idocaine is an amide-type local anesthetic and a class
Ib antidysrhythmic agent, available since 1948. Sys-
temic exposure to large amounts of it leads to adverse
effects on the cardiovascular and central nervous systems
(CNS). The primary mechanism of action is interrupting car-
diac and neural signal conduction by hindering the influx of
sodium ions via Na+-channels. Therefore, it can cause in-
creased depolarization threshold and abortive action poten-
tial (1, 2). Lidocaine toxicity is dosage-dependent and di-
rectly relative to its plasma concentration. Likewise, the pos-
sibility of lidocaine toxicity is considered to be clinically sig-
nificant at plasma concentrations higher than 6.0 mg/L (3-7).
∗Corresponding Author: Shahin Shadnia; Department of Clinical Toxicol-
ogy, Loghman-Hakim Hospital Poison Center, Kamali Avenue, South Karegar
Street, Tehran, Iran. Tel/Fax: +98-21-55424041 Email: shahin1380@yahoo.com
Diagnosis is done based on clinical presentation, blood levels
of lidocaine and imaging studies. Anaphylaxis, anxiety dis-
orders, cocaine toxicity, and conversion disorders should be
considered in differential diagnosis of patients. The leading
complications of lidocaine toxicity are cardiac arrest, local is-
chemia or nerve toxicities. Management of lidocaine toxicity
comes when airway compromises, and substantial hypoten-
sion, dysrhythmias, and seizures take place (8-10). Parenteral
form of lidocaine is the best-known source of poisoning, but
poisoning could also happen with topical spray formulation
(11). Despite the importance of lidocaine toxicity, there is
a scarcity of studies in this regard. The existing researches
are limited to either intravenous or oral poisoning. Here, we
present clinical presentation, management, and outcome of
acute poisoning cases with topical gel and spray forms of li-
docaine.
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Figure 1: Clinical symptoms of patients on admission based on the
consumed amount of lidocaine and their sex.
2. Methods
2.1. Study design and setting
In this retrospective cross-sectional study demographics,
clinical presentation, laboratory findings, management, and
outcome of lidocaine intoxicated patients (based on ICD10
definitions) admitted to Loghman Hakim Hospital, from
April 2007 to March 2014 were analyzed. This center is a
unique referral poisoning center placed in the capital of Iran,
Tehran. The study protocol was approved by ethics commit-
tee of Shahid Beheshti University of Medical Sciences and
researchers adhered to principles of Helsinki recommenda-
tions.
2.2. Participants
All cases who met the ICD10 codes of lidocaine toxicity who
were referred to the emergency department (ED) of the men-
tioned hospital during the study period were evaluated with-
out any sex or age limitation. Patients with incomplete
records, multidrug toxicity, and any history of seizure were
excluded.
2.3. Data gathering
Using documented patient profiles, a checklist contain-
ing demographics, clinical presentation, laboratory findings,
and the outcome was filled out for all included patients by
a senior toxicology resident. We converted the percentage
amount of lidocaine per dose to milligrams in order to bet-
ter report the results. Intensive care unit (ICU) admission in-
dications were considered as loss of consciousness, seizures,
cardiac dysrhythmias, and intubation.
2.4. Statistical Analysis
Data were analyzed using the statistical package for social
sciences (SPSS) and p-value under 0.05 was considered sta-
tistically significant. Continuous data were examined by stu-
dent t-test if the data were normally distributed (indicated
by Kolmogorov-Smirnov test); otherwise, Mann–Whitney U-
test was applied. Categorical data were compared using Pear-
son’s chi-square or Fisher’s exact test. Baseline demograph-
ics and screening measure variables were compared across
groups using chi-square for categorical variables and one-
factor (treatment) ANOVA for continuous variables.
3. Results
3.1. Baseline characteristics
30 cases of Lidocaine poisoning with the mean age of 21.83
± 6.57 (10-40) years were admitted to ED during the study
period (60% male). 18 (60%) cases were in 21-30 years age
group, 11 (36.7%) were in 10-20 years group, and 1 (3.3%)
was in 31-40 years age group. All subjects had used either
6.5% lidocaine spray or 2% topical formulations of lidocaine.
The most prevalent cause of poisoning was suicide attempt
(87.5%). The mean consumed dose of lidocaine was 465 ±
318.17 milligrams (11 cases < 500 milligrams and 19 cases ≥
500 milligrams). The average elapsed time between exposure
and admission to the emergency room was 5.1(1 – 76) hours.
3.2. Clinical and para-clinical manifestations
Figure 1 shows the clinical symptoms of patients on admis-
sion based on sex and amount of lidocaine consumption.
The most frequent clinical presentations were nausea and
vomiting (50%), seizure (33.3%), and loss of consciousness
(16.7%). Metabolic acidosis was seen in blood gas analysis of
all cases and 13 (43.3%) cases presented with some grades of
loss of consciousness. Table 1 summarizes clinical and labo-
ratory findings of studied patients based on their intention.
22 (73.3%) cases had normal sinus rhythm, 4 had (13.3%)
bradycardia, 2 (6.7%) had ventricular tachycardia, and 2
(6.7%) had left axis deviation on electrocardiography (ECG).
Brain computed tomography (CT) scan was performed
in three patients, which revealed hypoxic-ischemic en-
cephalopathy, and cortical atrophy.
3.3. Management and outcome
18 (60%) patients were treated with supportive care such as
intravenous fluid and anti-epileptic agents. 11 (36.6%) cases
were intubated and admitted to intensive care unit (ICU) for
6.91 ± 7.16 (1-24) days.
Three patients experienced status epilepticus that led to car-
diac arrest, and death (100% with sucidal intention). Mortal-
ity rate was 10%, and those who were discharged gained full
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recovery. Table 2 summarizes the characteristics of the three
deceased individuals.
4. Discussion
Based on the results of this study, most cases of topical lido-
caine toxicity were among < 40-year-old patients with male
to female ratio of 1.2, with a sucidal attempt in 90%, need for
intensive care in 36.6%, and mortality rate of 10%.
Previous investigations demonstrated parenteral formula-
tions of lidocaine as a source of accidental and intentional
poisoning (12-19). In the United States in 2015, 1334 single
exposures to lidocaine were reported (20).
Although in many case studies lidocaine toxicity has been re-
ported to happen inadvertently, we found 27 cases (90%) of
intentional ingestion in six years. To date, there is one case
report with two fatal subjects of deliberate consumption (13).
Most of the studies indicated that following lidocaine use,
only 35% of the consumed lidocaine reaches the systemic cir-
culation and 65% of it is rapidly absorbed and digested by the
liver hepatocytes. Full elimination of lidocaine occurs with a
half-life of 0.7-1.8 hours, and 3% of lidocaine is discharged
unchanged in the 24-hour urine (21-23). Nevertheless, the
peak clinical signs and symptoms of lidocaine toxicity are ob-
served 10-25 minutes after ingestion (12, 24, 25). The critical
fact is that distribution kinetics are not so imperative in un-
derstanding the course of effects or toxicity of lidocaine when
it is used for local anesthesia or after oral ingestion (26).
There is no specific treatment for lidocaine toxicity. Here, the
majority of cases received supportive care (60%). Thus, man-
agement is symptomatic to prevent hypoxia, acidosis, and
hyperkalemia, which may increase the risk of cardiac toxi-
city. Gastric decontamination is of partial value due to the
quick absorption after ingestion. Benzodiazepine and barbi-
turates can be prescribed to control local anesthetic-induced
seizure. Still, they may aggravate circulatory and respiratory
depression. Likewise, propofol has been used effectively to
end the seizure in subjects with lidocaine toxicity(27, 28).
Studies proved that toxicity would increase by acidosis (29)
and decreased by alkalosis (30). The majority of manifes-
tations in this study owed to neurotoxicity of lidocaine that
has been reported by other investigations as well (15, 31).
The clinical symptoms after consumption of approximately
two to more than 24 mg/ml of lidocaine are tongue numb-
ness, dizziness, auditory and visual disorders, loss of con-
sciousness, seizures, coma, and respiratory and cardiac ar-
rest. Eventually, in this study, three people underwent car-
diac arrest all of whom had previous experiences of neuro-
logical symptoms including decreased level of consciousness
and seizures.
In this research, mortality rate was 10%. So far, in most of the
studies, fatal cases of lidocaine toxicity were reported, either
accidental or intentional. The considerable point here is that
systemic toxicity of lidocaine can be life-threatening. Hence,
the rapid evaluation of clinical manifestations is essential to
prevent mortality.
In the current study, the mean consumed dosage of lidocaine
was 465 ± 318.17 mg/ml. This study was performed retro-
spectively; therefore, we could not find any evidence of li-
docaine assessment in the plasma samples. In general, lido-
caine is dose-related, and toxicity may emerge at 8 mg/L or
higher serum concentrations. Researchers revealed that li-
docaine toxicity could manifest by using high dosages of this
remedy and system hypersensitivity in individuals (21).
In this study, a significant portion of patients were male
(60%), and the most frequent age range was 21-30 years. In
one CDC survey between 1981-1983, 43,813 out of 51,880
workers with lidocaine toxicity were female (32). Following
reviewing all studies on “lidocaine poisoning/intoxication”
in PubMed and Google Scholar databases, we found seven
parallel studies. Five of the cases occurred in women, three
in men and one did not mention. The mean age of the vic-
tims was 47.25 years (12, 16, 33-37), which is higher than our
results. The difference may be because of accidental poison-
ing in the elderly.
This case series illustrated the relatively high suicidal rate in
lidocaine poisoning and focuses on the management of such
patients. Clinicians need to be aware of the possible toxicity
of topical or oral lidocaine and wisely review dosage sched-
ules and discuss potential toxicity with patients in addition
to allowing for alternative therapeutic modalities.
5. Limitation
Since this was a retrospective study, the primary limitation
was that the ingested dose of lidocaine was determined by
taking a history of the patients and some patients may not
have declared the exact dosage. Besides, lidocaine blood
level could not be evaluated because we do not have the
equipment in Iran. Therefore, serum lidocaine concentra-
tions must be determined in further studies.
6. Conclusion
Based on the results of this study, most cases of topical lido-
caine toxicity were among < 40 year old patients with a male
to female ratio of 1.2, with suicidal attempt in 90%, need for
intensive care in 36.6%, and mortality rate of 10%.
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Table 1: Clinical and laboratory findings of intubated patients based on their intention
Parameter Accidental (n=3) Suicidal (n=27) P
Vital signs
Systolic blood pressure (mm Hg) 106.67 ± 23.62 109.37 ± 21.88 0.948
Diastolic blood pressure(mm Hg) 72.50 ± 3.53 70.04 ± 12.68 0.523
Pulse rate (Beats/minute) 84.00 ± 10.58 84.30 ± 24.24 0.845
Respiratory rate (Beats/minute) 15.00 ± 4.24 17.54 ± 9.48 <0.001
Presentation
Loss of consciousness (Reed Scale) 2.67 ± 2.30 1.33 ± 1.79 0.424
Seizure 1 (3.3) 9 (30) <0.001
Metabolic acidosis 0 (0) 8 (26.6) 0.197
Laboratory findings
Lidocaine amount (milligrams)* 666.67 ± 288.67 442.59 ± 318.26 0.200
Aspartate Aminotransferase (U/L) 18.33 ± 0.57 36.04 ± 49.77 0.524
Alanine Aminotransferase (U/L) 13.00 ± 4.58 29.64 ± 41.72 0.391
Total Serum Bilirubin (mg/dL) 0.53 ± 0.25 0.58 ± 0.45 0.543
Creatinine (mg/dL) 1.70 ± 1.47 0.96 ± 0.24 0.016
Sodium (mmol/L) 140.33 ± 2.30 142.19 ± 3.67 0.300
Potassium (mmol/L) 3.73 ± 0.25 4.192± 0.72 0.130
Bicarbonate (mmol/L) 22.50± 3.06 24.21 ± 6.75 0.475
Serum Glucose (mg/dL) 131 ± 45.39 119.81 ± 58.11 0.389
Serum BUN (mg/dL) 20.33 ± 3.78 24.88 ± 7.58 0.196
∗: based on reports from patients or their companions. Data are presented as mean ± standard deviation or number (%).
Table 2: Complete characteristics of deceased cases of lidocaine poisoning
Variable Case 1 Case 2 Case 3
Demographics
Age (year) 20 21 27
Sex Male Male Male
Vital signs
Blood pressure (mmHg) 170/80 70/50 100/70
Pulse rate (/minutes) 100 72 109
Respiratory rate (/minutes) 12 12 12
Paraclinical findings
Lidocaine amount (mg) 250 250 1000
Conscioussness 4 3 4
ICU stay (days) 15 2 3
Metabolic acidosis Positive Positive Positive
Brain CT findings
Ischemic encephalopathy Ischemic encephalopathy –
Electrocardiographic findings
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